Document is current
Any future updates will be listed below
-
Authors
Elias, Harold K. https://orcid.org/0000-0002-6189-4752
Mitra, Sneha https://orcid.org/0000-0002-7718-8721
da Silva, Marina B.
Rajagopalan, Adhithi
Gipson, Brianna https://orcid.org/0009-0005-5837-8676
Lee, Nicole
Kousa, Anastasia I.
Ali, Mohamed A. E. https://orcid.org/0000-0003-2352-2760
Grassmann, Simon https://orcid.org/0000-0002-8336-3418
Raghuraman, Rhoshini https://orcid.org/0009-0002-8647-2465
Zhang, Xiaoqun C.
DeWolf, Susan
Smith, Melody https://orcid.org/0000-0002-2702-0381
Andrlova, Hana
Argyropoulos, Kimon V.
Sharma, Roshan https://orcid.org/0000-0001-9886-009X
Fei, Teng https://orcid.org/0000-0001-7888-1715
Sun, Joseph C.
Dunbar, Cynthia E. https://orcid.org/0000-0002-7645-838X
Park, Christopher Y. https://orcid.org/0000-0003-2018-3476
Leslie, Christina S. https://orcid.org/0000-0002-4571-5910
Bhandoola, Avinash https://orcid.org/0000-0002-4657-8372
Kharas, Michael G. https://orcid.org/0000-0002-1165-6991
van den Brink, Marcel R. M. https://orcid.org/0000-0003-0696-4401
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35-CA284024, 1R01CA193842-01)
Breakthrough Institute
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK101989-01A1)
- License Information
-
More Information
Article History
Received: 20 June 2024
Accepted: 14 June 2025
First Online: 4 July 2025
Competing interests
: M.R.M.vdB. has received research support and stock options from Seres Therapeutics and stock options from Notch Therapeutics and Pluto Therapeutics; he has received royalties from Wolters Kluwer; has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, WindMIL Therapeutics, Rheos Medicines, Merck & Co, Inc., Magenta Therapeutics, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Forty Seven Inc., Priothera, Ceramedix, Lygenesis, Pluto Therapeutics, GlaskoSmithKline, Da Volterra, Vor BioPharma, Novartis (Spouse), Synthekine (Spouse), and Beigene (Spouse); he has IP Licensing with Seres Therapeutics and Juno Therapeutics; and holds a fiduciary role on the Foundation Board of DKMS (a nonprofit organization). The Walter and Eliza Hall Institute of Medical Research receives milestone and royalty payments related to venetoclax. Employees are entitled to receive benefits related to these payments. M.G.K. is a member of the scientific advisory board of 858 Therapeutics, and the laboratory gets research support from AstraZeneca and Transition Bio. The remaining authors declare no competing interests.
